BeiGene Announces Clinical and Non-Clinical Data on BRUKINSA™ (Zanubrutinib) and Tislelizumab to Be Presented at the 25th European Hematology Association (EHA) Virtual Congress

Ads

You May Also Like

Pistol Bay Signs Exclusivity Agreement for Cannabinoid Herbal Blend

VANCOUVER, British Columbia, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Pistol Bay Mining Inc. (TSX-V ...

Immunocore Appoints Andrew Hotchkiss as Chief Commercial Officer

PRESS RELEASE Immunocore Appoints Andrew Hotchkiss as Chief Commercial Officer (Oxford, UK and Conshohocken, ...